Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.

Trial Profile

Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Rabies vaccine (Primary)
  • Indications Rabies
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 13 Dec 2011 Actual patient number (630) added as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Novartis Vaccines added as trial affiliate as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Primary endpoint identified as 'clinical response' as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top